Aventis Pharma’s net profit declined 65.58% to Rs 36.10 crore for the fourth quarter ended December 31, due to the acquisition of nutraceutical formulations business of Universal Medicare. The company had posted net profit of Rs 104.90 crore in the October-December period last year.
The company’s net sales rose to Rs 337.90 crore during the fourth quarter, as against Rs 286.50 crore in the same period previous year.
The profit for the quarter ended December 31, 2011 has been impacted due to the costs relating to the above acquisition and lower interest income as a result of the investment.
For the entire 2011, the company posted net profit of Rs 191.20 crore, as compared to Rs 230.70 crore in 2010. Net sales of the company for the year were Rs 1,229.70 crore, as against Rs 1,085 crore in 2010.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.95 |
| Dr. Reddys Lab | 1242.75 |
| Cipla | 1230.00 |
| Zydus Lifesciences | 935.00 |
| Lupin | 2337.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: